Know Cancer

forgot password

Phase 1b/2 Single-arm Trial Evaluating the Combination of Lapatinib, Everolimus and Capecitabine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer With CNS Progression After Trastuzumab

Phase 1/Phase 2
18 Years
Not Enrolling
Central Nervous System Metastases, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer

Thank you

Trial Information

Phase 1b/2 Single-arm Trial Evaluating the Combination of Lapatinib, Everolimus and Capecitabine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer With CNS Progression After Trastuzumab


I. Central nervous system (CNS) objective response rate at 12 weeks: defined as either a
complete response or partial response provided there is no progression of extra-CNS disease,
increasing steroid requirements, or worsening of neurologic signs and symptoms (NSS)^34
Lesions will be measured using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.


I. Safety and tolerability. II. Median progression free survival. III. Median overall
survival. IV. CNS objective response rate and clinical benefit rate (complete response,
partial response and stable disease lasting at least 6 months).

V. Extra-CNS objective response rate according to RECIST1.1.


Patients receive lapatinib ditosylate orally (PO) once daily (QD) and everolimus PO QD on
days 1-21, and capecitabine PO twice daily (BID) on days 1-14. Treatment repeats every 21
days for 17 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment or treatment discontinuation, patients will complete 2
follow up visits within 7 days and at 30 days and then will be followed for survival every 3
months for up to 12 months.

Inclusion Criteria:

- Patients with HER2+ (immunohistochemistry [IHC] 3+ or fluorescence in situ
hybridization [FISH]+ R/G > 2.0 or silver-enhanced in situ hybridization [SISH]+
HER2/chromosome 17 centromere [CEP17] > 2.0) breast cancer with documented central
nervous system (CNS) recurrence or progression

- Must have received trastuzumab (neoadjuvant, adjuvant or metastatic setting)

- At least one measurable lesion in the brain (>= 10 mm on T1-weighted,
gadolinium-enhanced magnetic resonance imaging [MRI]); (prior neurosurgical
resection, whole brain radiation or stereotactic radiation therapy is allowed
provided the patient has a measurable CNS progression [at least one new and/or
progressive measurable brain metastasis]; measurable or non-measurable extracranial
metastases allowed)

- Concurrent steroids allowed (up to equivalent of prednisone 20 mg daily, on taper or
stable dose for at least 2 weeks)

- Life expectancy of >= 12 weeks

- Previous treatment with other HER2 targeted agents allowed; (previous treatment with
HER2 inhibitors and investigational drugs to be discontinued prior to starting study
treatment [at least 21 days for trastuzumab and other antibodies; at least 14 days
for lapatinib; at least 5 half-lives for other agents])

- Previous chemotherapy (adjuvant and metastatic regimens) and hormonal therapy
allowed, but chemotherapy must have been discontinued at least 21 days prior to
starting study treatment and hormonal therapy at least 7 days prior to starting study
treatment; patients must have recovered from acute Common Terminology Criteria for
Adverse Events (CTCAE) v 4.0 grade >= 2 side effects of previous treatments

- At least 2 weeks since prior radiotherapy or stereotactic radiosurgery, and 4 weeks
since prior major surgery at time of study enrollment

- Eastern Cooperative Oncology Group (ECOG) performance status =< 2

- Absolute neutrophil count (ANC) >= 1.5 x 10^9/L

- Platelets >= 100 x 10^9/L

- Hemoglobin (Hb) >= 9 g/dL

- Serum bilirubin =< 1.5 x upper limit of normal (ULN) (=< 3.0 if Gilbert's syndrome)

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=<
5 x ULN in patients with liver metastases)

- International normalized ratio (INR) =< 1.5

- Adequate renal function: serum creatinine =< 1.5 x ULN

- Fasting serum cholesterol =< 300 mg/dL OR =< 7.75 mmol/L AND fasting triglycerides =<
2.5 x ULN; NOTE: In case one or both of these thresholds are exceeded, the patient
can only be included after initiation of appropriate lipid lowering medication

- Signed informed consent

- Age >= 18 years

Exclusion Criteria:

- Patients who have never received trastuzumab

- Prior treatment with an mammalian target of rapamycin (MTOR) inhibitor (including
everolimus, sirolimus, temsirolimus)

- Leptomeningeal carcinomatosis as only site of CNS disease

- Subjects who have current active hepatic or biliary disease (with exception of
patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable
chronic liver disease per investigator assessment)

- Patients with clinically significant interstitial lung disease or history of cardiac

- Patients, who have had a major surgery or significant traumatic injury within 4 weeks
of start of study drug, patients who have not recovered from the side effects of any
major surgery (defined as requiring general anesthesia) or patients that may require
major surgery during the course of the study

- Prior treatment with any investigational drug within the preceding 4 weeks prior to
starting study drug

- Patients receiving chronic, systemic treatment with corticosteroids (more than 20
mg/day prednisone equivalent, see inclusion criteria) or another immunosuppressive
agent; topical or inhaled corticosteroids are allowed

- Patients should not receive immunization with attenuated live vaccines within one
week of starting study drug or during study period; close contact with those who have
received attenuated live vaccines should be avoided during treatment with everolimus;
examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral
polio, Bacillus Calmette-Guérin (BCG), yellow fever, varicella and typhoid vaccine
live oral (TY)21a typhoid vaccines

- Other malignancies within the past 3 years except for adequately treated carcinoma of
the cervix or basal or squamous cell carcinomas of the skin

- Patients who have any severe and/or uncontrolled medical conditions or other
conditions that could affect their participation in the study such as:

- Symptomatic congestive heart failure of New York heart Association class III or

- Unstable angina pectoris, symptomatic congestive heart failure, myocardial
infarction within 6 months of start of study drug, serious uncontrolled cardiac
arrhythmia, left ventricular ejection fraction (LVEF) < 50% or any other
clinically significant cardiac disease

- Severely impaired lung function as defined as spirometry and diffusion capacity
of the lung of carbon monoxide (DLCO) that is 50% of the normal predicted value
and/or oxygen (02) saturation that is 88% or less at rest on room air

- Uncontrolled diabetes as defined by fasting serum glucose > 1.5 x ULN (Note:
optimal glycemic control should be achieved before starting trial therapy)

- Active (acute or chronic) or uncontrolled severe infections

- Liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class

- Note: A detailed assessment of hepatitis B/C medical history and risk factors
must be done at screening for all patients; hepatitis B virus (HBV)
deoxyribonucleic acid (DNA) and hepatitis C ribonucleic acid polymerase chain
reaction (HCV RNA PCR) testing are required at screening for all patients with a
positive medical history based on risk factors and/or confirmation of prior
HBV/HCV infection; patients with positive results for HBV/HCV infection will be
allowed in this study provided monitoring and prophylactic treatment are

- A known history of human immunodeficiency virus (HIV) seropositivity

- Impairment of gastrointestinal function or gastrointestinal disease that may
significantly alter the absorption of everolimus/lapatinib (lapatinib ditosylate)
(e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption
syndrome or small bowel resection)

- Patients with an active, bleeding diathesis

- Patients on warfarin (patients on injectable blood thinners, such as Lovenox, are
able to continue those)

- Female patients who are pregnant or breast feeding, or adults of reproductive
potential who are not using effective birth control methods; adequate contraception
must be used throughout the trial and for 8 weeks after the last dose of study drug,
by both sexes; (women of childbearing potential must have a negative urine or serum
pregnancy test within 7 days prior to administration of study drug)

- Male patient whose sexual partner(s) are women of childbearing potential (WOCBP) who
are not willing to use adequate contraception, during the study and for 8 weeks after
the end of treatment

- Patients with a known hypersensitivity to everolimus or other rapamycins (e.g.,
sirolimus, temsirolimus) or to its excipients

- History of noncompliance to medical regimens

- Patients unwilling to or unable to comply with the protocol

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

CNS objective response rate defined as either a complete response or partial response provided there is no progression of extra-CNS disease, increasing steroid requirements, or worsening of NSS measured using RECIST v1.1

Outcome Description:

Estimated with a 95% confidence interval. Chi-square test will be used evaluate if the CNS response rate at week 12 is significantly higher than 20%.

Outcome Time Frame:

12 weeks

Safety Issue:


Principal Investigator

Sara Hurvitz

Investigator Role:

Principal Investigator

Investigator Affiliation:

Jonsson Comprehensive Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

February 2013

Completion Date:

Related Keywords:

  • Central Nervous System Metastases
  • HER2-positive Breast Cancer
  • Male Breast Cancer
  • Recurrent Breast Cancer
  • Stage IV Breast Cancer
  • Breast Neoplasms
  • Neoplasm Metastasis
  • Breast Neoplasms, Male



Jonsson Comprehensive Cancer Center Los Angeles, California  90095